Adjuvant endocrine therapy is effective but the rates of patients not continuing therapy are high. In the present prospective observational study of 115 postmenopausal women starting endocrine therapy, 40.9% of the patients starting aromatase inhibitor therapy discontinued within the first year because of intolerable side effects. Baseline pain was associated with discontinuation. Future research should focus on proactive treatment of patients at a high risk of not continuing therapy. Background: Toxicity can lead to noncontinuation of adjuvant endocrine therapy. We hypothesized that endocrine therapy-induced changes in grip strength would predict for early discontinuation of therapy because of musculoskeletal toxicity and would be associated with a patient's body mass index. Patients and Methods: Postmenopausal women with breast cancer starting a new adjuvant endocrine therapy were enrolled in the present study. The patients were monitored for 12 months to assess their symptoms, endocrine therapy adherence and change in grip strength and baseline body mass index. The association between the change in grip strength and interval to discontinuation was assessed using a joint longitudinal and survival model. Results: Of the 93 aromatase inhibitor (AI)-treated and 22 tamoxifen-treated patients, 40.9% and 9% discontinued endocrine therapy within 12 months because of toxicity, respectively (P ¼ .019). A trend was seen toward a greater decrease in grip strength in the AI-treated patients over time (P ¼ .055); however, the decrease was not significantly associated with the interval to discontinuation (P ¼ .96). Receipt of an AI (hazard ratio, 5.49; P ¼ .019) and baseline pain (hazard ratio, 1.19; P ¼ .004) significantly decreased the interval to discontinuation. Conclusion: In contrast with the findings from previous reports, the change in grip strength in our study was not associated with the interval to discontinuation of AI therapy. Future research should focus on proactive treatment of patients at increased risk of AI intolerance, such as those with high levels of preexisting pain.
Introduction
Adjuvant aromatase inhibitors (AIs) and tamoxifen reduce the recurrence in, and mortality of, patients with hormone receptorpositive breast cancer. 1 The 3 third-generation AIs in routine clinical use, including 2 nonsteroidal compounds (anastrozole and letrozole) and a steroidal compound (exemestane), have similar benefit and toxicity profiles according to direct and cross-trial comparisons. 2 Despite the excellent disease outcomes with anti-endocrine therapy, 20% of patients will not continue with AI therapy, primarily owing to the toxicity of the treatment.
3,4 AI-associated toxicity, which is primarily musculoskeletal, negatively affects the quality of life of breast cancer survivors 5 and can result in worse breast cancer outcomes. 4, 6 Despite considerable research, the mechanism that underlies this AI-associated musculoskeletal syndrome remains unknown. In addition, only a few predictors of developing toxicity have been identified, including previous chemotherapy, a shorter interval since menopause, and, possibly, obesity.
Tenosynovitis at the wrist and loss of grip strength after the initiation of AI therapy was identified in a small cohort of AI-treated patients. 10 Subsequently, associations between the loss of grip strength and both musculoskeletal symptoms and extremes of body mass index (BMI) were noted in AI-treated patients that were not evident in tamoxifen-treated patients. 11, 12 We conducted a prospective observational study of postmenopausal women starting adjuvant endocrine therapy to validate these findings in a patient population with a greater proportion of obese patients. We hypothesized that patients with decreased grip strength during AI therapy would be more likely to discontinue treatment and would be more likely to have either a low or a high BMI. We also examined the patient-reported symptom experience of patients treated with AIs versus tamoxifen and the endocrine therapy patterns of patients who discontinued initially prescribed AI therapy because of toxicity.
Patients and Methods

Patients
Eligible patients were recruited from a single institution (University of Michigan Medical Center) from September 2009 through July 2013 (ClinicalTrials.gov identifier, NCT01223833). Postmenopausal women with stage 0 to III breast cancer who were scheduled to receive adjuvant endocrine therapy with tamoxifen (Nolvadex) or a third-generation AI (anastrozole, exemestane, letrozole) were eligible. The choice of endocrine therapy was at the discretion of the patient and the treating provider. All surgery, chemotherapy, and radiation therapy were completed before the initiation of adjuvant endocrine therapy. Previous tamoxifen and AI therapy were permitted, although patients were required to have discontinued the medication for ! 4 weeks before enrollment. No enrolled patients had previously received AI therapy. Patients were ineligible if they had a pre-existing major rheumatologic disorder or concomitant use of sex hormone-containing medications or luteinizing hormone receptor hormone agonist therapy. The University of Michigan institutional review board approved the present study, and all the patients provided written informed consent before participation in any protocol-directed procedures.
Study Design
After enrollment, all the patients underwent a baseline assessment before initiation of adjuvant endocrine therapy. The assessments included measurement of height, weight, hip and waist circumferences, bilateral grip strength, questionnaires, and phlebotomy. The choice of endocrine therapy was at the discretion of the treating physician. Each assessment was repeated at 3, 6, and 12 months after the initiation of adjuvant endocrine therapy. If a patient changed from 1 AI to another during study participation, the assessments were continued and the timing of the assessments was determined from the original treatment start date.
The grip strength was measured using a modified sphygmomanometer (Martin Vigorimeter Measuring Instrument; Albert Waeschle Ltd, Dorset, UK). The patients squeezed the balloon of the instrument 3 times with each hand, and the maximal force from each of the 6 assessments was recorded. The maximum value for either the right or left hand at each measurement point was used.
At each assessment, the patients rated their average pain during the previous 7 days using an 11-point Likert scale. At 3, 6, and 12 months, the patients also completed a questionnaire to more comprehensively assess the musculoskeletal and menopausal symptoms experienced and their perception of the association between the symptoms and the endocrine therapy using a 5-point Likert scale (from "definitely not due to medication" to "definitely due to medication"). Adherence to therapy was also assessed using the Medication Adherence Report Scale-5 questionnaire. 13 
Statistical Analysis
For continuous data, including grip strength, BMI, waist-to-hip ratio, and baseline demographic data, between-group differences were assessed using the Wilcoxon rank sum test. Between-group differences for categorical variables were determined using the c 2 test or Fisher's exact test. Spearman's correlation was used to assess the association between right and left hand maximum grip strength, the baseline maximum grip strength, and the baseline BMI and waist-to-hip ratio. The Kaplan-Meier method and log-rank test were used to compare the interval to discontinuation of endocrine therapy (defined as the earlier of treatment discontinuation or the end of the study at 1 year) between the AI-and tamoxifen-treated patients. Cox proportional hazards models were used to evaluate the associations between the interval to discontinuation of endocrine therapy and baseline anthropometric factors, controlling for the type of endocrine therapy.
The primary endpoint was the effect of BMI on grip strength after 12 months of therapy based on preliminary data. 12 However, no effect of BMI or its quadratic term was identified when added to a multivariable model in the primary analysis. Therefore, the association among the change in grip strength, the baseline BMI, and the interval to discontinuation of first therapy was examined using a joint longitudinal and survival model that accounted for missing data. The association between the change in grip strength and the development of new or worsening musculoskeletal symptoms (defined as arthralgias or myalgias) was assessed using a generalized linear model (generalized estimating equations). The presence of patient-reported symptoms was compared between treatment groups using the c 2 test or Fisher's exact test. For all P values reported, no correction for multiple testing was applied.
Results
Patients
Of the 115 patients enrolled in the trial, 93 initiated therapy with an AI and 22 with tamoxifen (Table 1) . Of the 93 patients who started AI therapy, 76 (81.7%) received anastrozole, 16 (17.2%) received letrozole, and 1 (1.1%) received exemestane. The median age of all patients was 62 years (range, 41-79 years). The average BMI was 30.1 AE 7.1 kg/m 2 ; 42% of the AI-treated patients had a BMI of ! 30 kg/m 2 . Of the AI-treated patients, 64% reported muscle or joint pain in the 3 months before enrollment. The average score for muscle and joint pain for all patients in the week before enrollment was 2.3 AE 2.1 on an 11-point scale. In this postmenopausal population, all baseline patient characteristics were well-balanced between the 2 groups, with the exception that more AI-treated patients had received adjuvant chemotherapy (P ¼ .004) and more tamoxifen-treated patients had a history of thyroid abnormalities (P ¼ .005). At baseline, the grip strength in the right and left hands correlated strongly (Spearman's correlation, r ¼ 0.79; P < .001). No correlations between the baseline maximum grip strength and BMI (r ¼ 0.01; P ¼ .94) or waist-to-hip ratio (r ¼ À0.15; P ¼ .10) at baseline were identified.
Adherence and Continuation With Endocrine Therapy
Adherence was assessed using the Medication Adherence Report Scale-5 questionnaire. Two thirds of the patients (66 of 99) reported always taking the medication as prescribed at all assessments and the other 16 patients did not complete the MARS-5, primarily because they had discontinued treatment prior to the 3 month assessment. Of the 33 patients who reported not always taking it as prescribed 26 (78.8%) reported forgetting to take the medication rarely or sometimes, 5 (15.2%) reported intentionally missing a dose rarely, and 4 patients had either stopped taking the medication for a while or had altered the dose. The rates of nonadherence were similar between the AI-and tamoxifen-treated patients (36% vs. 32%, respectively).
After 1 year of study participation, 75 of the 115 patients (65.2%) reported they were still taking the initially prescribed endocrine therapy. Of the 93 patients treated with an AI, 38 (40.9%) had discontinued the initial AI medication during the first year. In contrast, of the 22 patients treated with tamoxifen, 2 (9.0%) had stopped taking it (P ¼ .019; Supplemental Figure 1 [available in the online version]). Of the 38 AI-treated patients who discontinued their initial therapy, 28 (74%) reported doing so at least in part because of arthralgia or other musculoskeletal symptoms.
Of the 38 patients who discontinued initial AI medication within the first year of therapy, 31 (82%) initiated treatment with a second AI, 4 started tamoxifen, and 3 opted for no endocrine therapy (Supplemental Figure 1A; Figure 1B ; available in the online version). Of the 31 patients who started treatment with a second AI, 18 (51%) discontinued treatment from the second AI within the first year of therapy; 76% reported musculoskeletal symptoms as one of the reasons for discontinuation.
Associations Between Baseline Factors and Interval to AI Discontinuation
The AI-treated patients had a significantly increased risk of discontinuing their initial treatment compared with the tamoxifentreated patients (hazard ratio, 5.49; 95% confidence interval, 1.32-22.80; P ¼ .019; Figure 1) . Controlling for the difference between treatment types, only greater baseline pain was significantly associated with a greater risk of discontinuing therapy (hazard ratio, 1.19; 95% confidence interval, 1.06-1.35; P ¼ .004; Table 2 ). Neither age nor previous taxane chemotherapy was associated with the interval to AI discontinuation.
Association of Grip Strength, BMI, and Interval to Discontinuation of Initial Endocrine Therapy
The average maximum grip strength gradually decreased between baseline and 12 months for the AI-treated patients with measurements but not for the tamoxifen-treated patients ( Table 3 ). The baseline BMI was not associated with the change in grip strength (P ¼ .88). Although a borderline significant difference was found in the change in grip strength during the study period between those taking tamoxifen and those taking an AI (P ¼ .055) such that grip strength decreased more over time for those receiving AI therapy, the change in grip strength during the study period was not significantly associated with the interval to discontinuation of the first therapy (P ¼ .96) or with new or worsened musculoskeletal symptoms (P ¼ .87).
Patient-reported Symptoms During Endocrine Therapy
More than 80% of patients reported pain during treatment with either an AI or tamoxifen, with similar rates for all sites of pain reported for the 2 classes of medication (Supplemental Tables 1-3 ; available in the online version). However, a greater proportion of patients reported that their aches and pains were probably or definitely related to the AI medication compared with tamoxifen (53.5% vs. 13.3%; P ¼ .005). Similar findings were noted for joint stiffness but not for myalgias or carpal tunnel syndrome. In contrast to the similar incidence of pain between the 2 cohorts, more patients reported new or worsening numbness during AI therapy compared with tamoxifen therapy (39.5% vs. 15%; P ¼ .041).
Of the other assessed symptoms, only the incidence of vaginal discharge was different between the 2 cohorts, with a greater rate in tamoxifen-treated patients (35% vs. 8%; P ¼ .004), although the drug attribution was similar between the 2 medications. Although the incidence of hot flashes was similar between the 2 cohorts, more patients attributed the hot flashes to taking tamoxifen than to taking an AI (100% vs. 72.6%; P ¼ .017).
Discussion
In the present study, we have confirmed the high rate of initial endocrine therapy discontinuation because of toxicity in postmenopausal women receiving AI therapy. Poor adherence and noncontinuation of treatment have implications for breast cancer outcomes, because both have been shown to be associated with increased breast cancer mortality. 4, 6 However, no reliable predictors of intolerance have yet been identified. We have confirmed that baseline pain is a predictor of treatment discontinuation. However, we were unable to confirm our hypothesis that those patients who experienced more loss of grip strength during therapy would be more likely to discontinue treatment early. In addition, neither the baseline grip strength nor the baseline BMI was predictive of treatment discontinuation. Therefore, neither the baseline grip strength nor the change in grip strength during treatment should be used to predict which patients will be more likely to experience poor tolerance to AI therapy. The present study was performed to validate a previous report that decreased grip strength and discontinuation of AI therapy because of AI-associated musculoskeletal syndrome were associated with extremes of BMI. 12 However, although we identified a borderline significant decrease in grip strength in AI-treated patients compared with tamoxifen-treated patients, we were unable to validate the previously reported association with BMI. The reason for this discrepancy is unclear, although one potential explanation is the differences in BMI distribution among the enrolled patients in the 2 studies. In the previous study, the average BMI was 26 kg/m 2 and the maximum BMI was 41 kg/m 2 . In contrast, in the present study, the average BMI was > 30 kg/m 2 and the maximum BMI was 50 kg/m 2 . Another possible reason for the discrepancy is differences in clinical practice. Because the endpoint was discontinuation of therapy because of toxicity, the providers at 1 institution might have been more likely to recommend treatment discontinuation compared with those at another institution, which would have influenced the findings. Only 15% of patients in the original University of Leuven study discontinued AI therapy, in contrast to the 40% in the present report of patients treated at the University of Michigan. This decrease in medication persistence could have resulted in dilution of the perceived effects on discontinuation by the baseline BMI if patients with less severe symptoms had discontinued therapy.
In the present study of a postmenopausal cohort of women with early-stage breast cancer, we demonstrated a statistically significant greater rate of early discontinuation of AI therapy compared with tamoxifen. However, our observational study was not randomized, and, presumably, reasons such as comorbidities were present that resulted in 1 drug being chosen over the other as initial therapy. Importantly, previously identified potential predictors of developing musculoskeletal toxicity, including median age, average BMI, and average pain at treatment initiation, were similar between the 2 groups. This finding suggests that aromatase inhibition causes more bothersome toxicities than does treatment with tamoxifen.
Discontinuation of AI therapy continued throughout the study period and did not plateau. This finding is similar to that from other previously reported trials of AI therapy, including the ATAC (Arimidex Tamoxifen Alone or in Combination trial), which demonstrated a continued increase in discontinuation throughout the 5 years of therapy, especially in the first year. 9 However, it remains unclear whether the symptoms that develop early in the treatment course have a different etiology than those that become bothersome later, and whether alternative management approaches are required. Efforts to improve the tolerance of, and persistence with, AI therapy are critical to optimizing breast cancer outcomes. This is particularly important in light of the newer data supporting extended adjuvant endocrine therapy and the superiority of AI therapy combined with ovarian suppression or ablation for premenopausal women at high risk of breast cancer recurrence. 14, 15 As studies have previously reported, 3, 16 we have demonstrated that some patients who are unable to tolerate the first AI medication switched to a second AI medication, with a minority able to persist with the second AI. This suggests that one potential option for management could be intermittent discontinuation of therapy, although the implications of this approach on risk of disease recurrence are unknown. In addition, more than one half of our patients subsequently discontinued the second AI, also because of toxicity; thus, this strategy is not likely to be successful for most patients.
Reducing the toxicity of AI therapy has been challenging. The only randomized interventions that have demonstrated improvement are acupuncture and exercise, both of which resulted in moderate improvements in symptoms. 17, 18 In addition, we have reported encouraging phase II results with duloxetine. This observation is currently being tested in a phase III randomized clinical trial (ClinicalTrials.gov identifier, NCT01598298). 19 However, most 
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interventions tested are only implemented once a patient has reported treatment-emergent symptoms. It is unknown whether upfront management of pre-existing symptoms in this population with a high prevalence of baseline musculoskeletal symptoms would result in better long-term tolerance of therapy. Efforts to use educational interventions to improve adherence have been tested but thus far have been unsuccessful. [20] [21] [22] More research is needed to identify effective prevention and management strategies for this vexing toxicity.
Conclusion
Patient continuation with adjuvant endocrine therapy continues to be less than optimal. The identification of both the predictors of, and the mechanisms underlying, the development of toxicity is important for the design of preventative approaches. From our findings, neither the assessment of grip strength nor the baseline BMI appears to be a useful surrogate for an increased risk of developing bothersome AI toxicity. However, in the present study, we have confirmed that pre-existing pain at AI initiation is associated with an increased risk of treatment discontinuation and should be a focus of future management approaches. Lessening toxicity will lead to increased continuation with therapy, which, in turn, could lead to improved breast cancer outcomes.
Clinical Practice Points
Musculoskeletal pain is prevalent in postmenopausal women with breast cancer treated with adjuvant endocrine therapy. Noncontinuation with AI therapy because of toxicity is common. The results of the present study have demonstrated that patients with pre-existing pain could be at increased risk of intolerance to AI therapy. Future research should focus on proactive treatment of patients at high risk of noncontinuation of AI therapy because of toxicity.
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